Medtronic Highlights Affera Momentum and FDA Breakthrough Device Designation
On April 26, 2026, Medtronic (MDT) announced continued progress for its Affera family of technologies used in cardiac arrhythmia treatment. Positive data from clinical trials were presented at the Heart Rhythm Society Annual Meeting and a new trial was initiated to evaluate broader atrial fibrillation patient populations.
Tickers: $MDT
Topics: atrial fibrillation (Afib) cardiac arrhythmia FDA Breakthrough Device Designation